Login / Signup

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine.

Katerina Pavenski
Published in: TH open : companion journal to thrombosis and haemostasis (2021)
An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.
Keyphrases
  • case report
  • coronavirus disease
  • sars cov
  • high dose
  • free survival
  • low dose
  • diffuse large b cell lymphoma
  • binding protein
  • respiratory syndrome coronavirus
  • stem cell transplantation
  • hodgkin lymphoma